Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

61
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
61
Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

1.3K
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
1.3K
Pharmacodynamic Models: Linear Concentration–Effect Model01:15

Pharmacodynamic Models: Linear Concentration–Effect Model

56
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing...
56
Nonlinear Pharmacokinetics: Causes of Nonlinearity01:22

Nonlinear Pharmacokinetics: Causes of Nonlinearity

876
Nonlinearity in drug pharmacokinetics is caused by various factors influencing how a drug is absorbed, distributed, metabolized, and excreted. Understanding these nonlinear processes is crucial for predicting drug behavior in the body and optimizing drug dosing regimens.
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
876
Tumor Progression02:07

Tumor Progression

7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Pharmacodynamic Models: Logarithmic Concentration–Effect Model01:15

Pharmacodynamic Models: Logarithmic Concentration–Effect Model

62
The log-linear model is a pharmacological framework used to describe the relationship between drug concentration and its effect. This model is particularly relevant when the observed effects range between 20% and 80% of the drug’s maximum effect (Emax), where a near-linear relationship is observed between the log of drug concentration and the measured effect. However, the log-linear model does not predict the maximum possible effect (Emax) or the effect at zero drug concentration,...
62

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standard knee radiographs enable deep learning inference of MRI-defined cartilage and meniscal damage in early knee osteoarthritis: a study using the osteoarthritis initiative database.

Frontiers in physiology·2026
Same author

MSTune: A Data-Driven Approach to Parameter Tuning Using Grid Search and Differential Evolution for Gas Chromatography-Mass Spectrometry-Based Compound Identification.

Metabolites·2026
Same author

Machine Learning-Enabled In Situ Diagnostics for Intelligent Plasma-Based Semiconductor Manufacturing: A Review.

ACS applied materials & interfaces·2026
Same author

A Novel Drug Candidate that Selectively Targets the Critical Androgen Receptor-ELK1 Growth Axis in Advanced and Drug-Resistant Prostate Cancer.

bioRxiv : the preprint server for biology·2026
Same author

Ethnic Differences in the Presentation Patterns of Type 3 Macular Neovascularization.

Retina (Philadelphia, Pa.)·2026
Same author

Designable van der Waals Crystal for Artificial Neuronal Cell Mimicking.

Advanced materials (Deerfield Beach, Fla.)·2026
Same journal

PROSPECTIVELY ESTIMATING THE AGE OF INITIATION OF E-CIGARETTES AMONG U.S. YOUTH: FINDINGS FROM THE POPULATION ASSESSMENT OF TOBACCO AND HEALTH (PATH) STUDY, 2013-2017.

Journal of biometrics & biostatistics·2021
Same journal

Simple Power and Sample Size Estimation for Non-Randomized Longitudinal Difference in Differences Studies.

Journal of biometrics & biostatistics·2019
Same journal

Deep Learning Methods for Predicting Disease Status Using Genomic Data.

Journal of biometrics & biostatistics·2019
Same journal

Methods for the Analysis of Missing Data in FMRI Studies.

Journal of biometrics & biostatistics·2019
Same journal

Methods for Analysis of Pre-Post Data in Clinical Research: A Comparison of Five Common Methods.

Journal of biometrics & biostatistics·2018
Same journal

Power Estimation in Planning Randomized Two-Arm Pre-Post Intervention Trials with Repeated Longitudinal Outcomes.

Journal of biometrics & biostatistics·2018
See all related articles

Related Experiment Video

Updated: Mar 26, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K

A Bayesian nonlinear mixed-effects disease progression model.

Seongho Kim1, Hyejeong Jang1, Dongfeng Wu2

  • 1Biostatistics Core, Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201.

Journal of Biometrics & Biostatistics
|January 23, 2016
PubMed
Summary
This summary is machine-generated.

This study introduces advanced Bayesian disease progression models accounting for age variations. The new approach provides detailed age-specific and population-level insights into disease sensitivity and progression.

Keywords:
Cancer ScreeningNonlinear Mixed-effects ModelsSensitivitySojourn Time

More Related Videos

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

3.8K
A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

21.1K

Related Experiment Videos

Last Updated: Mar 26, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K
Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

3.8K
A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

21.1K

Area of Science:

  • Biostatistics
  • Epidemiology
  • Medical Informatics

Background:

  • Disease progression models are crucial for understanding disease trajectories.
  • Incorporating age-related variations can enhance model accuracy.
  • Current models may not fully capture age-specific disease dynamics.

Purpose of the Study:

  • To develop a nonlinear mixed-effects Bayesian framework for disease progression.
  • To generalize probability models for sensitivity based on age at diagnosis, preclinical time, and sojourn time.
  • To apply and compare these models with traditional methods.

Main Methods:

  • Nonlinear mixed-effects modeling in a Bayesian framework.
  • Generalization of probability models for sensitivity.
  • Bayesian Markov chain Monte Carlo (MCMC) estimation.
  • Application to Johns Hopkins Lung Project and HIPGNY data.

Main Results:

  • Developed age-dependent disease progression models.
  • Obtained age-specific individual-level distributions for sensitivity, sojourn time, and transition probability.
  • Achieved population-level distributions for these key parameters.
  • Demonstrated improved estimation by considering age-related random effects.

Conclusions:

  • The developed nonlinear mixed-effects Bayesian models effectively incorporate age variation in disease progression.
  • These models provide richer, age-specific insights into disease dynamics.
  • The approach offers a more comprehensive understanding of sensitivity, preclinical duration, and transition probabilities.